CI Global Health Sciences Corporate Class

Series P USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date May 2017
CAD Total net assets ($CAD)
As at 2026-10-30
$262.8 million
NAVPS
As at 2026-11-11
$11.2092
MER (%)
As at 2026-03-31
0.24
Management fee (%) 0.90
Units outstanding
As at
-
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.1669

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

P 90324
A ISC 301
DSC SO* 401
LL SO 1401
F 324
*No new purchases directly into switch only funds.

Performance2 As at 2026-10-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
5.55% -1.74% 4.40% 15.42% 20.04% 5.54% 2.29% - 5.38%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.1669
2021-03-26 0.0563
2020-12-18 0.0892
2020-09-25 0.0844
2020-06-26 0.0615
Payable date Total
2020-03-20 0.1428
2019-12-13 0.0890
2019-09-27 0.0991
2019-06-21 0.0930
2019-03-22 0.1458

Management team

First we'll display the Team Company and then the Team members
Matthew Strauss

CI Global Health Sciences Corporate Class

Series P USD
 
Portfolio allocations4 As at 2026-10-31
Asset allocation (%)
  • US Equity 77.34
  • International Equity 18.94
  • Canadian Corporate Bonds 2.44
  • Cash and Equivalents 1.30
  • Other -0.02
Sector allocation (%)
  • Healthcare 93.70
  • Fixed Income 2.44
  • Exchange Traded Fund 2.05
  • Cash and Cash Equivalent 1.30
  • Other 0.51
Geographic allocation(%)
  • United States 76.82
  • Switzerland 8.43
  • United Kingdom 6.65
  • Netherlands 3.88
  • Canada 3.13
  • Europe 0.57
  • Other 0.51
  • Denmark 0.01
Top holdings6
Sector (%)
1. Eli Lilly and Co Drugs 10.99%
2. AbbVie Inc Drugs 8.12%
3. Johnson & Johnson Drugs 6.89%
4. AstraZeneca PLC Drugs 6.65%
5. Thermo Fisher Scientific Inc Healthcare Equipment 5.56%
6. UnitedHealth Group Inc Healthcare Services 5.15%
7. Abbott Laboratories Healthcare Equipment 5.11%
8. Vertex Pharmaceuticals Inc Drugs 4.77%
9. Stryker Corp Healthcare Equipment 4.77%
10. Merck & Co Inc Drugs 4.56%
11. DexCom Inc Healthcare Equipment 4.16%
12. Danaher Corp Healthcare Equipment 4.08%
13. argenx SE Drugs 3.88%
14. Lonza Group AG Drugs 3.47%
15. Gilead Sciences Inc Drugs 3.38%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.